Management Approach for Elderly Patients with Rising A1C on Metformin

Individualized A1C Target Selection

The American Diabetes Association recommends an A1C target of <7.0-7.5% for healthy elderly patients with few comorbidities and intact cognition/function 2, 3, 4
For complex or intermediate health elderly patients with multiple comorbidities and mild to moderate cognitive impairment, the target A1C is <8.0% 2, 1, 4
For very complex or poor health elderly patients with end-stage illness or moderate to severe cognitive impairment, the focus should be on symptom management rather than A1C targets 1, 5

The American College of Clinical Endocrinologists recommends avoiding sulfonylureas in elderly patients due to the increased risk of hypoglycemia 6, 5
The American Geriatrics Society suggests that GLP-1 receptor agonists are a suitable first-line addition to metformin for elderly patients with an A1C >9% 5

The American Diabetes Association advises against targeting an A1C <6.5% in elderly patients, as it may increase the risk of all-cause mortality, cardiovascular death, and severe hypoglycemia 7
The American Geriatrics Society recommends avoiding the use of first-generation sulfonylureas in elderly patients due to the risk of severe hypoglycemia 6, 5

The American Association of Clinical Endocrinologists recommends reassessing A1C in 3 months after treatment intensification 5
The American Geriatrics Society suggests screening for hypoglycemia at each visit, as elderly patients may present atypically with confusion or dizziness 5

For patients ≥80 years old or with limited life expectancy (<10 years), the target A1C should be <8.0-8.5% rather than <7% 8, 5
The American College of Clinical Endocrinologists recommends prioritizing avoiding hypoglycemia over tight glycemic control in elderly patients with advanced age or limited life expectancy 8, 5